Evidence map›Paper›PMID 24634223›Full record

ArticleThe Journal of biological chemistry2014

Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein.

Mohammad S Eram, Susan P Bustos, Evelyne Lima-Fernandes, Alena Siarheyeva, Guillermo Senisterra, Taraneh Hajian, Irene Chau, Shili Duan, Hong Wu, Ludmila Dombrovski and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 116 citations in OpenAlex.

  1. Why recombination hotspots?PLoS genetics · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mechanisms and rationales of SAM homeostasis.Trends in biochemical sciences · 2025
    Review
  8. Epigenetic Regulation of CD8European journal of immunology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Mohammad S EramStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Susan P BustosStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Evelyne Lima-FernandesStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Alena SiarheyevaStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Guillermo SenisterraStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Taraneh HajianStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Irene ChauStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Shili DuanOntario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
Hong WuStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Ludmila DombrovskiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7.
Matthieu SchapiraStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8.
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7; Ontario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
Masoud VedadiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8. Electronic address: m.vedadi@utoronto.ca.
University of Toronto · CAOntario Institute for Cancer Research · CA

Funding

CIHRWellcome Trust 092809Wellcome Trust 092809/Z/10/Z
6 · The paper itself

Abstract

PRDM9 (PR domain-containing protein 9) is a meiosis-specific protein that trimethylates H3K4 and controls the activation of recombination hot spots. It is an essential enzyme in the progression of early meiotic prophase. Disruption of the PRDM9 gene results in sterility in mice. In human, several PRDM9 SNPs have been implicated in sterility as well. Here we report on kinetic studies of H3K4 methylation by PRDM9 in vitro indicating that PRDM9 is a highly active histone methyltransferase catalyzing mono-, di-, and trimethylation of the H3K4 mark. Screening for other potential histone marks, we identified H3K36 as a second histone residue that could also be mono-, di-, and trimethylated by PRDM9 as efficiently as H3K4. Overexpression of PRDM9 in HEK293 cells also resulted in a significant increase in trimethylated H3K36 and H3K4 further confirming our in vitro observations. Our findings indicate that PRDM9 may play critical roles through H3K36 trimethylation in cells.

Indexed as

DNA MethylationCalorimetryHistone-Lysine N-MethyltransferaseHistonesHumansKineticsLysineMass SpectrometrySubstrate SpecificityHistone-Lysine N-MethyltransferaseHistonesLysinePRDM9 protein, humanCancerEnzyme InhibitorsEnzyme KineticsEpigeneticsHistone MethylationMethyltransferase

Identifiers

PMID24634223
PMCPMC4002121
OpenAlexW2007010532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.